Ohio Doc Loses DEA License Over State Permit Slip
Published Date: 7/7/2025
Notice
Summary
Dr. Loretta Clement from Ohio lost her DEA registration because she no longer has the state permission to handle controlled substances. She didn’t ask for a hearing, so the revocation went through automatically. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting her medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Clement
The DEA revoked Certificate of Registration No. FC2337500 for Loretta Clement, M.D., because she no longer has state authority to handle controlled substances in Ohio. The revocation takes effect August 6, 2025, and means she may not legally prescribe, administer, dispense, or otherwise handle controlled drugs under federal law.
Pending and New Ohio Registrations Denied
The DEA also denied any pending applications by Loretta Clement, M.D., to renew or modify her registration and denied any other pending application for additional registration in Ohio. This denial is effective August 6, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-12604, Withdrawal of the Notice of Intent To Prepare a Supplemental Environmental Impact Statement (SEIS) for the Columbia River System Operations
The U.S. Army Corps of Engineers and Bureau of Reclamation have decided not to move forward with extra environmental studies for the Columbia River System. This means no new delays or extra costs for communities and businesses relying on the river’s operations. Everyone can expect things to keep running as planned without any surprise changes.
Next: 2025-12624, Sunshine Act Meetings
The Legal Services Corporation is holding its summer meetings July 14-16, 2025, in Detroit, and most sessions will be open for the public to watch live or in person. Some parts might close for sensitive topics like budget plans, investigations, or legal updates. These meetings affect board members, committees, and anyone interested in how legal aid is managed, with no new costs announced.